Faecal Analyses in Rheumatoid Arthritis Therapy (FART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03775824|
Recruitment Status : Active, not recruiting
First Posted : December 14, 2018
Last Update Posted : December 21, 2018
This study evaluates the intestinal microbiome and disease activity in patients with rheumatoid arthritis receiving immunosuppressive therapy. Patients will be analysed at two time points in reference to two predefined primary endpoints:
- Changes in intestinal microbiome
- Response to therapy
The investigators want to evaluate if successful treatment of rheumatoid arthritis coincide with specific changes in the gut flora.
|Condition or disease||Intervention/treatment|
|Rheumatoid Arthritis||Drug: MTX start Drug: TNF start|
Methotrexate (MTX) and tumor necrosis factor (TNF) -inhibitors are two efficient medications for the treatment of rheumatoid arthritis. In a substantial number of cases however, these medications remain ineffective. At present, the scientific community has limited understanding of why some patients are resistant to these medications. The purpose of this study is to understand if the gut flora may associate with treatment response.
Recent studies have associated rheumatoid arthritis with intestinal dysbiosis. Specifically, the bacteria Prevotella copri, has been associated with this disease, an observation that has been supported also by mechanistic studies. In patients receiving methotrexate, normalization of dysbiosis has been associated with successful treatment.
This study is of observational character and integrated in the routine clinical care of patients with rheumatoid arthritis at the Rheumatology Clinic, Skane University Hospital, Lund, Sweden. Study participants are asked to deliver blood and fecal sampling at two time-points together with clinical evaluation of disease activity. With an estimated inclusion of 50 patients, at least 20 responders and 20 non-responders are expected to be included and to be compared to each other.
If successful treatment response in rheumatoid arthritis is associated with specific alterations of the gut flora, these results may guide future studies on the impact of dysbiosis and probiotics on this disease.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Faecal Analyses in Rheumatoid Arthritis Therapy: An Prospective Observational Study of the Intestinal Microbiome in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy|
|Actual Study Start Date :||August 1, 2016|
|Actual Primary Completion Date :||November 1, 2018|
|Estimated Study Completion Date :||June 1, 2019|
Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
Drug: MTX start
Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
Other Name: MTX
Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
Drug: TNF start
Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
Other Name: TNF
- Intestinal gut flora in rheumatoid arthritis [ Time Frame: Analysis made at study start/baseline ]Intestinal gut flora based on DNA-based microbial analysis of fecal samples
- Change in gut flora [ Time Frame: Change from baseline Dysbiosis Index Score at 6 months ]
Change in Dysbiosis Index Score at follow up compared to baseline.
The Dysbiosis Index Score measures degree of intestinal dysbiosis on a scale from 1 to 5, where 5 indicates dysbiosis. The Index has been extensively described at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029765/
- Change in disease activity/treatment response at follow up [ Time Frame: Change from baseline DAS-28 at 6 months ]Change in Disease Activity Score 28 (DAS-28), an established index of disease activity in rheumatoid arthritis between 0-10, where 10 equals maximum activity.
- Adherance to immunosuppressive therapy [ Time Frame: Analysis made at 6 months follow up ]Is the patient still prescribed the same immunosuppressant compared to baseline?
- Change in intestinal concentration Prevotella [ Time Frame: Change from baseline concentration at 6 months ]Alterations in intestinal concentrations of Prevotella bacteria according to polymerase chain reaction (PCR)-based analysis
- Change in intestinal concentration Lactobacillus [ Time Frame: Change from baseline concentration at 6 months ]Alterations in intestinal concentrations of Lactobacillus bacteria according to PCR-based analysis
- Change in intestinal concentration Clostridia [ Time Frame: Change from baseline concentration at 6 months ]Alterations in intestinal concentrations of Clostridia bacteria according to PCR-based analysis
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03775824
|Principal Investigator:||Kristofer Andréasson, MD PhD||Skane University Hospital|